Get the Stockscreener App
1.57
2.48%
-0.04
After Hours:
1.57
Evaxion Biotech A S Adr stock is traded at $1.57, with a volume of 55,549.
It is down -2.48% in the last 24 hours and down -43.12% over the past month.
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
See More
Previous Close:
$1.61
Open:
$1.66
24h Volume:
55,549
Relative Volume:
1.05
Market Cap:
$9.44M
Revenue:
-
Net Income/Loss:
$-24.47M
P/E Ratio:
-1.602
EPS:
-0.98
Net Cash Flow:
$-24.56M
1W Performance:
+12.14%
1M Performance:
-43.12%
6M Performance:
-61.14%
1Y Performance:
-80.62%
1-Day Range:
$1.55
$1.83
1-Week Range:
$1.30
$1.83
52-Week Range:
$1.28
$13.61
Evaxion Biotech A S Adr Stock (EVAX) Company Profile
Name
Evaxion Biotech A S Adr
Sector
Industry
Phone
-
Address
-
Compare EVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion Biotech A S Adr
|
1.57 | 9.44M | 0 | -24.47M | -24.56M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Evaxion Biotech A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion Biotech A S Adr Stock (EVAX) Latest News
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
Evaxion Biotech stock hits 52-week low at $1.31 By Investing.com - Investing.com South Africa
Evaxion Biotech stock hits 52-week low at $1.31 - Investing.com
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower - MSN
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
Evaxion appeals Nasdaq delisting determination - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply Friday, Up 2.7% for Week - MSN
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Close Bearish Week on High Note Friday - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Evaxion Biotech Reports Q3 Progress and Financials - TipRanks
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5% - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise Friday - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Ends Week Higher in Friday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
Evaxion reports improved AI vaccine target predictions - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
Evaxion Biotech A/S ADR (EVAX) Stock: From Low to High in 52 Weeks - The InvestChronicle
EVAX’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Evaxion Biotech inks vaccine licensing deal with MSD - Investing.com
Evaxion stock jumps on expanded vaccine development pact with MSD (NASDAQ:EVAX) - Seeking Alpha
H.C. Wainwright keeps buy rating on Evaxion stock, cites promising AI-powered cancer vaccine - Investing.com
Evaxion Biotech enhances AI vaccine discovery platform - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - MSN
Evaxion reports promising phase 2 trial results for cancer vaccine - Investing.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
Evaxion reports high response rate in melanoma trial - Investing.com
Evaxion reports breakthrough in gonorrhea vaccine research - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com India
Evaxion Biotech A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):